Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study.
antibodies, neoplasm
immunotherapy
liver neoplasms
programmed cell death 1 receptor
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
accepted:
06
07
2020
entrez:
2
9
2020
pubmed:
2
9
2020
medline:
16
9
2021
Statut:
ppublish
Résumé
Nivolumab is Food and Drug Administration approved in sorafenib-experienced, advanced hepatocellular carcinoma (HCC). Post-registration data of treatment in a real-world setting is lacking. We performed an international, multicenter observational study to confirm safety and efficacy of nivolumab in 233 patients treated outside clinical trials from eight centers in North America, Europe and Asia. Patients received nivolumab for Barcelona Clinic Liver Cancer stage C (n This study confirms safety and efficacy of nivolumab in advanced HCC across various lines of therapy and degrees of liver dysfunction. Despite equal ORR and toxicity to nivolumab, patients with CP-B functional class have shorter survival than the patients with CP-A.
Sections du résumé
BACKGROUND
Nivolumab is Food and Drug Administration approved in sorafenib-experienced, advanced hepatocellular carcinoma (HCC). Post-registration data of treatment in a real-world setting is lacking.
PATIENTS AND METHODS
We performed an international, multicenter observational study to confirm safety and efficacy of nivolumab in 233 patients treated outside clinical trials from eight centers in North America, Europe and Asia.
RESULTS
Patients received nivolumab for Barcelona Clinic Liver Cancer stage C (n
CONCLUSIONS
This study confirms safety and efficacy of nivolumab in advanced HCC across various lines of therapy and degrees of liver dysfunction. Despite equal ORR and toxicity to nivolumab, patients with CP-B functional class have shorter survival than the patients with CP-A.
Identifiants
pubmed: 32868393
pii: jitc-2020-001033
doi: 10.1136/jitc-2020-001033
pmc: PMC7462152
pii:
doi:
Substances chimiques
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
ID : PS3416
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: DP received lecture fees from ViiV Healthcare, Bayer Healthcare and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, Astra Zeneca; received research funding (to institution) from MSD, BMS. DB has received lecture and speaker fees from Bayer Healthcare and the Falk Foundation Germany. LR received lecture fees from AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, Roche, Sanofi; advisory board/consulting fees from Amgen, ArQule, AstraZeneca, Basilea, Bayer, Celgene, Eisai, Exelixis, Hengrui, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi; travel expenses from Ipsen; received research funding (to institution) from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Roche. NP received lecture fees from AbbVie and Gilead; travel expenses from ArQule. YHH has received advisory board/consulting fees for BMS, MSD, Bayer Healthcare, IPSEN, EISAI, Gilead and Lilly. AS received research funding (to institution) from AstraZeneca, Exelixis, BMS and Clovis; advisory board/consulting fees from BMS, AstraZeneca, and Exelixis.
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Cancer Cell Int. 2018 Mar 20;18:44
pubmed: 29568237
Clin Cancer Res. 2009 Feb 1;15(3):971-9
pubmed: 19188168
Cancer. 2019 Sep 15;125(18):3234-3241
pubmed: 31154669
Gastroenterology. 2018 Jan;154(1):128-139
pubmed: 28989060
World J Gastroenterol. 2019 Feb 21;25(7):789-807
pubmed: 30809080
Nat Rev Clin Oncol. 2016 Mar;13(3):143-58
pubmed: 26598942
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
J Gastroenterol. 2009;44 Suppl 19:136-41
pubmed: 19148808
Oncogene. 2020 Apr;39(18):3620-3637
pubmed: 32157213
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Aliment Pharmacol Ther. 2018 Sep;48(6):598-609
pubmed: 30039640
Cancers (Basel). 2020 Jan 11;12(1):
pubmed: 31940757
Int J Cancer. 2011 Feb 15;128(4):887-96
pubmed: 20473887
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
pubmed: 30285213
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Aliment Pharmacol Ther. 2019 May;49(10):1323-1333
pubmed: 30980420
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754
pubmed: 29654146
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Gut. 2015 May;64(5):842-8
pubmed: 25666193
Ann Oncol. 2013 Feb;24(2):406-411
pubmed: 23041587
J Hepatol. 2017 Aug;67(2):302-309
pubmed: 28336466
Hepatobiliary Pancreat Dis Int. 2016 Jun;15(3):234-56
pubmed: 27298100
Hepatology. 2014 Nov;60(5):1776-82
pubmed: 24912948
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
J Hepatol. 2014 Dec;61(6):1385-96
pubmed: 25135860
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869